Gap junction modifier rotigaptide decreases the susceptibility to ventricular arrhythmia by enhancing conduction velocity and suppressing discordant alternans during therapeutic hypothermia in isolated rabbit hearts

Yu Cheng Hsieh, Jiunn Cherng Lin, Chen Ying Hung, Cheng Hung Li, Shien-Fong Lin, Hung I. Yeh, Jin Long Huang, Chu Pin Lo, Ketil Haugan, Bjarne D. Larsen, Tsu Juey Wu

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background Therapeutic hypothermia (TH) may increase the susceptibility to ventricular arrhythmias by decreasing ventricular conduction velocity (CV) and facilitating arrhythmogenic spatially discordant alternans (SDA). Objective The purpose of this study was to test the hypothesis that rotigaptide, a gap junction enhancer, can increase ventricular CV, delay the onset of SDA, and decrease the susceptibility to pacing-induced ventricular fibrillation (PIVF) during TH. Methods Langendorff-perfused isolated rabbit hearts were subjected to 30-minute moderate hypothermia (33°C) followed by 20-minute treatment with rotigaptide (300 nM, n = 8) or vehicle (n = 5). The same protocol was also performed at severe hypothermia (30°C; n = 8 for rotigaptide, n = 5 for vehicle). Using an optical mapping system, epicardial CV and SDA threshold were evaluated by S1 pacing. Ventricular fibrillation inducibility was evaluated by burst pacing for 30 seconds at the shortest pacing cycle length (PCL) that achieved 1:1 ventricular capture. Results Rotigaptide increased ventricular CV during 33°C (PCL 300 ms, from 76 ± 6 cm/s to 84 ± 7 cm/s, P =.039) and 30°C (PCL 300 ms, from 62 ± 6 cm/s to 68 ± 4 cm/s, P =.008). Rotigaptide decreased action potential duration dispersion at 33°C (P =.01) and 30°C (P =.035). During 30°C, SDA thresholds (P =.042) and incidence of premature ventricular complexes (P =.025) were decreased by rotigaptide. PIVF inducibility was decreased by rotigaptide at 33°C (P =.039) and 30°C (P =.042). Rotigaptide did not change connexin43 expressions and distributions during hypothermia. Conclusion Rotigaptide protects the hearts against ventricular arrhythmias by increasing ventricular CV, delaying the onset of SDA, and reducing repolarization heterogeneity during TH. Enhancing cell-to-cell coupling by rotigaptide might be a novel approach to prevent ventricular arrhythmias during TH.

Original languageEnglish (US)
Pages (from-to)251-261
Number of pages11
JournalHeart Rhythm
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Induced Hypothermia
Gap Junctions
Cardiac Arrhythmias
Rabbits
Ventricular Fibrillation
Hypothermia
Epicardial Mapping
rotigaptide
Optical Devices
Connexin 43
Ventricular Premature Complexes
Action Potentials

Keywords

  • Cardiac alternans
  • Conduction velocity
  • Gap junction
  • Hypothermia
  • Optical mapping

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Gap junction modifier rotigaptide decreases the susceptibility to ventricular arrhythmia by enhancing conduction velocity and suppressing discordant alternans during therapeutic hypothermia in isolated rabbit hearts. / Hsieh, Yu Cheng; Lin, Jiunn Cherng; Hung, Chen Ying; Li, Cheng Hung; Lin, Shien-Fong; Yeh, Hung I.; Huang, Jin Long; Lo, Chu Pin; Haugan, Ketil; Larsen, Bjarne D.; Wu, Tsu Juey.

In: Heart Rhythm, Vol. 13, No. 1, 01.01.2016, p. 251-261.

Research output: Contribution to journalArticle

Hsieh, Yu Cheng ; Lin, Jiunn Cherng ; Hung, Chen Ying ; Li, Cheng Hung ; Lin, Shien-Fong ; Yeh, Hung I. ; Huang, Jin Long ; Lo, Chu Pin ; Haugan, Ketil ; Larsen, Bjarne D. ; Wu, Tsu Juey. / Gap junction modifier rotigaptide decreases the susceptibility to ventricular arrhythmia by enhancing conduction velocity and suppressing discordant alternans during therapeutic hypothermia in isolated rabbit hearts. In: Heart Rhythm. 2016 ; Vol. 13, No. 1. pp. 251-261.
@article{005727394a1447e6b5a4722e0f43b089,
title = "Gap junction modifier rotigaptide decreases the susceptibility to ventricular arrhythmia by enhancing conduction velocity and suppressing discordant alternans during therapeutic hypothermia in isolated rabbit hearts",
abstract = "Background Therapeutic hypothermia (TH) may increase the susceptibility to ventricular arrhythmias by decreasing ventricular conduction velocity (CV) and facilitating arrhythmogenic spatially discordant alternans (SDA). Objective The purpose of this study was to test the hypothesis that rotigaptide, a gap junction enhancer, can increase ventricular CV, delay the onset of SDA, and decrease the susceptibility to pacing-induced ventricular fibrillation (PIVF) during TH. Methods Langendorff-perfused isolated rabbit hearts were subjected to 30-minute moderate hypothermia (33°C) followed by 20-minute treatment with rotigaptide (300 nM, n = 8) or vehicle (n = 5). The same protocol was also performed at severe hypothermia (30°C; n = 8 for rotigaptide, n = 5 for vehicle). Using an optical mapping system, epicardial CV and SDA threshold were evaluated by S1 pacing. Ventricular fibrillation inducibility was evaluated by burst pacing for 30 seconds at the shortest pacing cycle length (PCL) that achieved 1:1 ventricular capture. Results Rotigaptide increased ventricular CV during 33°C (PCL 300 ms, from 76 ± 6 cm/s to 84 ± 7 cm/s, P =.039) and 30°C (PCL 300 ms, from 62 ± 6 cm/s to 68 ± 4 cm/s, P =.008). Rotigaptide decreased action potential duration dispersion at 33°C (P =.01) and 30°C (P =.035). During 30°C, SDA thresholds (P =.042) and incidence of premature ventricular complexes (P =.025) were decreased by rotigaptide. PIVF inducibility was decreased by rotigaptide at 33°C (P =.039) and 30°C (P =.042). Rotigaptide did not change connexin43 expressions and distributions during hypothermia. Conclusion Rotigaptide protects the hearts against ventricular arrhythmias by increasing ventricular CV, delaying the onset of SDA, and reducing repolarization heterogeneity during TH. Enhancing cell-to-cell coupling by rotigaptide might be a novel approach to prevent ventricular arrhythmias during TH.",
keywords = "Cardiac alternans, Conduction velocity, Gap junction, Hypothermia, Optical mapping",
author = "Hsieh, {Yu Cheng} and Lin, {Jiunn Cherng} and Hung, {Chen Ying} and Li, {Cheng Hung} and Shien-Fong Lin and Yeh, {Hung I.} and Huang, {Jin Long} and Lo, {Chu Pin} and Ketil Haugan and Larsen, {Bjarne D.} and Wu, {Tsu Juey}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.hrthm.2015.07.023",
language = "English (US)",
volume = "13",
pages = "251--261",
journal = "Heart Rhythm",
issn = "1547-5271",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Gap junction modifier rotigaptide decreases the susceptibility to ventricular arrhythmia by enhancing conduction velocity and suppressing discordant alternans during therapeutic hypothermia in isolated rabbit hearts

AU - Hsieh, Yu Cheng

AU - Lin, Jiunn Cherng

AU - Hung, Chen Ying

AU - Li, Cheng Hung

AU - Lin, Shien-Fong

AU - Yeh, Hung I.

AU - Huang, Jin Long

AU - Lo, Chu Pin

AU - Haugan, Ketil

AU - Larsen, Bjarne D.

AU - Wu, Tsu Juey

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background Therapeutic hypothermia (TH) may increase the susceptibility to ventricular arrhythmias by decreasing ventricular conduction velocity (CV) and facilitating arrhythmogenic spatially discordant alternans (SDA). Objective The purpose of this study was to test the hypothesis that rotigaptide, a gap junction enhancer, can increase ventricular CV, delay the onset of SDA, and decrease the susceptibility to pacing-induced ventricular fibrillation (PIVF) during TH. Methods Langendorff-perfused isolated rabbit hearts were subjected to 30-minute moderate hypothermia (33°C) followed by 20-minute treatment with rotigaptide (300 nM, n = 8) or vehicle (n = 5). The same protocol was also performed at severe hypothermia (30°C; n = 8 for rotigaptide, n = 5 for vehicle). Using an optical mapping system, epicardial CV and SDA threshold were evaluated by S1 pacing. Ventricular fibrillation inducibility was evaluated by burst pacing for 30 seconds at the shortest pacing cycle length (PCL) that achieved 1:1 ventricular capture. Results Rotigaptide increased ventricular CV during 33°C (PCL 300 ms, from 76 ± 6 cm/s to 84 ± 7 cm/s, P =.039) and 30°C (PCL 300 ms, from 62 ± 6 cm/s to 68 ± 4 cm/s, P =.008). Rotigaptide decreased action potential duration dispersion at 33°C (P =.01) and 30°C (P =.035). During 30°C, SDA thresholds (P =.042) and incidence of premature ventricular complexes (P =.025) were decreased by rotigaptide. PIVF inducibility was decreased by rotigaptide at 33°C (P =.039) and 30°C (P =.042). Rotigaptide did not change connexin43 expressions and distributions during hypothermia. Conclusion Rotigaptide protects the hearts against ventricular arrhythmias by increasing ventricular CV, delaying the onset of SDA, and reducing repolarization heterogeneity during TH. Enhancing cell-to-cell coupling by rotigaptide might be a novel approach to prevent ventricular arrhythmias during TH.

AB - Background Therapeutic hypothermia (TH) may increase the susceptibility to ventricular arrhythmias by decreasing ventricular conduction velocity (CV) and facilitating arrhythmogenic spatially discordant alternans (SDA). Objective The purpose of this study was to test the hypothesis that rotigaptide, a gap junction enhancer, can increase ventricular CV, delay the onset of SDA, and decrease the susceptibility to pacing-induced ventricular fibrillation (PIVF) during TH. Methods Langendorff-perfused isolated rabbit hearts were subjected to 30-minute moderate hypothermia (33°C) followed by 20-minute treatment with rotigaptide (300 nM, n = 8) or vehicle (n = 5). The same protocol was also performed at severe hypothermia (30°C; n = 8 for rotigaptide, n = 5 for vehicle). Using an optical mapping system, epicardial CV and SDA threshold were evaluated by S1 pacing. Ventricular fibrillation inducibility was evaluated by burst pacing for 30 seconds at the shortest pacing cycle length (PCL) that achieved 1:1 ventricular capture. Results Rotigaptide increased ventricular CV during 33°C (PCL 300 ms, from 76 ± 6 cm/s to 84 ± 7 cm/s, P =.039) and 30°C (PCL 300 ms, from 62 ± 6 cm/s to 68 ± 4 cm/s, P =.008). Rotigaptide decreased action potential duration dispersion at 33°C (P =.01) and 30°C (P =.035). During 30°C, SDA thresholds (P =.042) and incidence of premature ventricular complexes (P =.025) were decreased by rotigaptide. PIVF inducibility was decreased by rotigaptide at 33°C (P =.039) and 30°C (P =.042). Rotigaptide did not change connexin43 expressions and distributions during hypothermia. Conclusion Rotigaptide protects the hearts against ventricular arrhythmias by increasing ventricular CV, delaying the onset of SDA, and reducing repolarization heterogeneity during TH. Enhancing cell-to-cell coupling by rotigaptide might be a novel approach to prevent ventricular arrhythmias during TH.

KW - Cardiac alternans

KW - Conduction velocity

KW - Gap junction

KW - Hypothermia

KW - Optical mapping

UR - http://www.scopus.com/inward/record.url?scp=84955701215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955701215&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2015.07.023

DO - 10.1016/j.hrthm.2015.07.023

M3 - Article

C2 - 26188250

AN - SCOPUS:84955701215

VL - 13

SP - 251

EP - 261

JO - Heart Rhythm

JF - Heart Rhythm

SN - 1547-5271

IS - 1

ER -